Business context and reporting period
Sunshine Heart, Inc. (now known as Nuwellis, Inc.) filed this Form 10-Q for the quarter and six months ended June 30, 2016. It was an early-stage medical-device company developing heart-failure therapies. The filing reports unaudited results under U.S. GAAP.
Financial performance and liquidity
- Revenue: $0 for Q2 2016 and $0 for the first half of 2016, versus $0 and $59,000, respectively, in 2015. The C-Pulse system was not approved for commercial sale.
- Losses: Q2 operating expenses were $3.982 million and net loss was $4.188 million ($0.23 per share), compared with $6.339 million and $6.358 million ($0.35 per share) in Q2 2015. First-half operating expenses were $8.537 million and net loss was $8.974 million ($0.49 per share), compared with $13.390 million and $13.421 million ($0.75 per share) in 2015.
- Margins: Not meaningful given no Q2 revenue; the filing does not provide a clear gross-margin measure.
- Cash flow: First-half cash used in operations was $9.136 million, investing cash use was $29,000, and financing cash use was $1.895 million. Cash declined by $11.064 million to $12.049 million from $23.113 million at year-end 2015.
- Debt and liquidity: At June 30, current debt was $3.938 million and long-term debt, net of discount and fees, was $1.965 million. The company reported $6.1 million outstanding under its Silicon Valley Bank facility and was in covenant compliance at quarter-end. Accumulated deficit was $162.2 million. Management stated continued operations depend on raising capital and commercializing products, and warned that unsuccessful fundraising could threaten its ability to continue as a going concern.
Material changes versus prior comparable periods
- Q2 SG&A fell 39.9% to $1.412 million; first-half SG&A fell 39.1% to $2.761 million. The company attributed the declines to streamlining and lower stock-based compensation.
- Q2 R&D declined 35.6% to $2.570 million; first-half R&D declined 34.8% to $5.776 million, primarily after enrollment ended in the COUNTER HF and OPTIONS HF studies.
- First-half interest expense doubled to $436,000, mainly reflecting the Silicon Valley Bank debt.
- Cash from financing shifted from $15.055 million provided in first-half 2015 to $1.895 million used in first-half 2016, as the prior period included debt borrowings and stock-sale proceeds while 2016 included debt repayments.
Outlook, subsequent events, and risks
- Management expected R&D spending to decrease during 2016, with potential increases later as development of a fully implantable system and the new clinical strategy advanced. The company did not expect clinical-study revenue in 2016. It expected an Australian R&D tax-credit refund in Q3 2016; the amount was not stated.
- On July 11, the company announced a pivot from counterpulsation toward neuromodulation, which management believed could offer a less costly development path, faster commercialization, and broader access to NYHA Class III patients. These were expectations, not assured outcomes.
- On July 26, it closed a preferred-stock financing for approximately $3.5 million gross, with conversion shares and warrants that could cause substantial dilution.
- On August 5, it acquired the Aquadex FlexFlow product line for $4.0 million cash and 1.0 million common shares. The transaction included additional seller rights and obligations, including participation rights in certain future financings. Integration, manufacturing, supply, competition, product-liability, regulatory, and commercialization risks were highlighted.
- After quarter-end, the company repaid its prior bank facility for approximately $6.0 million and entered a new facility of up to $5.0 million. Borrowings are subject to conditions, including financial covenants the company said it did not then meet; availability should not be assumed.
- Management reported disclosure controls were effective at a reasonable-assurance level. No material legal proceedings were reported.
Important facts for investors to verify
- Whether the July financing and subsequent debt arrangements provide adequate operating runway, given ongoing cash burn and covenant conditions.
- Actual progress, costs, regulatory requirements, and clinical evidence for the neuromodulation strategy and fully implantable system.
- Aquadex integration, product demand, manufacturing and supplier continuity, and any resulting costs or liabilities.
- The potential dilution and terms associated with preferred-stock conversion, warrants, and seller financing rights.
- Whether the company can sustain operations and reach commercialization without additional capital.